top of page

The co-founder of the startup Ousia Pharma describes working from Copenhagen's BioInnovation Institute on his company's next-generation enhancer to GLPs

blonca9
Oct 10, 2024
1 min read

Anders Bue Klein describes how the BI has made it easier for founders like him to take work from university and turn it into a company. Plus, why Ousia is conjugating NMDAs to GLPs in an attempt to improve their utility through enhanced neuroplasticity.

Recent Posts

AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions

AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions

As independent tenant advocates, Savills can help biotech and pharma companies make their real estate footprint align with their objectives and be more efficient

As independent tenant advocates, Savills can help biotech and pharma companies make their real estate footprint align with their objectives and be more efficient

NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment

NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page